Statement: The most common adverse events in the primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts.
Primary_evidence: Adverse Events 1:   Total: 267/744 (35.89%)   Neutropenia *2/744 (0.27%)   Anaemia *1/744 (0.13%)   Leukopenia *1/744 (0.13%)   Thrombocytopenia *1/744 (0.13%)   Thrombotic thrombocytopenic purpura *1/744 (0.13%)   Atrial flutter *1/744 (0.13%)   Cardiac arrest *1/744 (0.13%)   Myocardial ischaemia *1/744 (0.13%)   Arrhythmia *0/744 (0.00%)   Cardiac failure congestive *0/744 (0.00%) Adverse Events 2:   Total: 67/736 (9.10%)   Neutropenia *1/736 (0.14%)   Anaemia *0/736 (0.00%)   Leukopenia *0/736 (0.00%)   Thrombocytopenia *0/736 (0.00%)   Thrombotic thrombocytopenic purpura *0/736 (0.00%)   Atrial flutter *0/736 (0.00%)   Cardiac arrest *0/736 (0.00%)   Myocardial ischaemia *0/736 (0.00%)   Arrhythmia *2/736 (0.27%)   Cardiac failure congestive *1/736 (0.14%)
Secondary_evidence: Adverse Events 1:   Total: 6   Atrial fibrillation 1/67 (1.49%)   Ventricular fibrillation 1/67 (1.49%)   Gastrointestinal perforation 1/67 (1.49%)   Periproctitis 1/67 (1.49%)   General physical health deterioration 1/67 (1.49%)   Escherichia sepsis 1/67 (1.49%)   Pneumonia 1/67 (1.49%)   Tumour pain 1/67 (1.49%)   Renal failure acute 1/67 (1.49%)   Pleurisy 1/67 (1.49%)